Exited Portfolio Companies
Aglaia is looking for excellent cancer research with the potential to be translated into cancer medicines. This translates specifically in:
- Early-stage oncology drug development
- Disruptive science with the potential to transform cancer diagnosis and therapy
- Spread across different drug modalities (small molecules, biologicals, etc.) and drug development phases (from target discovery up to clinical development)
Inventions should have a potential to be superior to standard of care treatment at time of market introduction and should lead to clear benefits for cancer patients and society. Inventions should be preferably platform technologies but highly interesting drug candidates with first in class potential are also considered. Drug candidates must be rigorously validated in relevant and predictive preclinical cancer models. Evidence must be provided that inventions can be patented.